Back to Search Start Over

Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary.

Authors :
Rieckmann P
Centonze D
Giovannoni G
Hua LH
Oreja-Guevara C
Selchen D
Sørensen PS
Vermersch P
Wiendl H
Salloukh H
Yamout B
Source :
Neurodegenerative disease management [Neurodegener Dis Manag] 2023 Feb; Vol. 13 (1), pp. 5-13. Date of Electronic Publication: 2022 Oct 24.
Publication Year :
2023

Abstract

What Is This Summary About?: People with multiple sclerosis (shortened to MS) who are taking cladribine tablets may have concerns about whether they can be vaccinated against COVID-19. This summary details the findings from a previously published article, in which an international committee of 10 MS experts developed recommendations to answer some important questions about COVID-19 vaccines in people with MS (including relapsing-remitting or active secondary progressive disease) taking cladribine tablets.<br />What Were the Results?: The committee identified 13 recommendations, which were all agreed upon by at least three-quarters (75%) of the 38 voting MS experts. Generally, they recommended that people with MS taking cladribine tablets should be vaccinated for COVID-19 as soon as possible, because the vaccine is thought to be both safe and effective, and vaccine responses were not likely to be affected by cladribine tablets.<br />What Do the Results Mean?: Overall, people with MS taking cladribine tablets should receive the COVID-19 vaccine to protect themselves, unless advised differently by their healthcare provider.

Details

Language :
English
ISSN :
1758-2032
Volume :
13
Issue :
1
Database :
MEDLINE
Journal :
Neurodegenerative disease management
Publication Type :
Academic Journal
Accession number :
36278394
Full Text :
https://doi.org/10.2217/nmt-2022-0027